{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:14:01Z","timestamp":1790723641551,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.amjcard.2023.08.078","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:38:05Z","timestamp":1694180285000},"page":"31-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"206","author":[{"given":"Hanako","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-7639","authenticated-orcid":false,"given":"Ayumi","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.08.078_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0055-2016","article-title":"Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience","volume":"26","author":"Sitbon","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/VHRM.S2477","article-title":"Treprostinil for pulmonary hypertension","volume":"4","author":"Skoro-Sajer","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0003","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/2045893217719250","article-title":"Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension","volume":"7","author":"Kingman","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0004","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.rmed.2012.10.023","article-title":"Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension","volume":"107","author":"Minai","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0006","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0007","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/2045893217706357","article-title":"A systematic review of transition studies of pulmonary arterial hypertension specific medications","volume":"7","author":"Sofer","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0008","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.healun.2013.06.008","article-title":"One-year experience with intravenous treprostinil for pulmonary arterial hypertension","volume":"32","author":"Benza","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0009","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0010","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1513\/AnnalsATS.201305-115LE","article-title":"Massive ascites in pulmonary arterial hypertension: caution with epoprostenol","volume":"10","author":"Kataoka","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0011","doi-asserted-by":"crossref","first-page":"e12092","DOI":"10.1002\/pul2.12092","article-title":"Epoprostenol-associated ascites in pulmonary arterial hypertension","volume":"12","author":"Schoenberg","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0012","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1378\/chest.08-1323","article-title":"Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension","volume":"135","author":"Chin","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2023.08.078_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020969103","article-title":"Severe thrombocytopenia in patients with idiopathic pulmonary arterial hypertension provided several strategies for lung transplantation","volume":"10","author":"Kobayashi","year":"2020","journal-title":"Pulm Circ"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923008457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923008457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:48:23Z","timestamp":1757573303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923008457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":13,"alternative-id":["S0002914923008457"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.078","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}